Eli Lilly's Q4 FY24 guidance adjustment is due ... the company has launched a single-dose 2.5 mg and 5 mg Zepbound vials in the U.S. exclusively through LillyDirect for less than half the list ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

Best of luck, and do keep in touch. … When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens ...

Visible healing of the intestinal lining was observed in 46% of subjects treated with the therapy. Credit: SewCreamStudio/Shutterstock. Eli Lilly has received ...

Eli Lilly pre-announced the following drug numbers for Q4: Mounjaro — $3.5 billion, up from $3.1 billion in Q3 Zepbound — $1.9 billion, up from $1.26 billion in Q3. The biopharma reported ...

Similar to third-quarter 2024, management stated that sales of both Mounjaro and Zepbound were hurt ... ingredient semaglutide — a direct competitor to Lilly’s tirzepatide.

SAN FRANCISCO — When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens, it framed the move as a way ...

Shares of Eli Lilly have been falling in recent months ... Mounjaro ($3.1 billion) and Zepbound ($1.3 billion). Late last year, regulators approved Zepbound as a treatment option for adults ...

Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls in sales could portend weaker long-term potential for this market. Lilly is positioned to remain the ...